Vor Biopharma announces $100M public offering of 10M shares at $10 each to fund telitacicept development

Vor Biopharma Inc.

10,000,000 shares at $10.00 each; expected net proceeds ~$93.7M (or $107.8M if underwriters' option fully exercised).
Proceeds to advance telitacicept clinical development including Phase 3 trial for primary Sjögren's Disease, plus manufacturing/pre-commercialization.
Offering expected to close November 12, 2025; underwriters have 30-day option for up to 1,500,000 additional shares.
As of Sept 30, 2025, outstanding shares were 9,026,922; offering represents ~111% dilution if fully exercised.
Company believes current cash plus proceeds will fund operations into Q2 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.